NCT02893371: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies |
|
|
| Terminated | N/A | 1037352 | US | Lithium Carbonate, Lithobid, Lamotrigine, Lamictal, Valproic Acid, Depakote, Valproate, Oxcarbazepine, Trileptal, Carbamazepine, Equetro, Ziprasidone, Geodon, Risperidone, Risperdal, Quetiapine, Seroquel, Olanzapine, Zyprexa, Aripiprazole, Abilify, Fluoxetine / Olanzapine, Symbyax, Haloperidol, Haldol Decanoate, Perphenazine, Trilafon, Clozapine, Clozaril, Asenapine, Saphris, Lurasidone, Latuda, Paliperidone, Invega, Mirtazapine, Remeron, Remeronsoltab, Bupropion, Zyban, Aplenzin, Wellbutrin, Desvenlafaxine, Pristiq, Desfax, Duloxetine, Cymbalta, Irenka, Venlafaxine, Effexor XR, Citalopram, Celexa, Escitalopram, Lexapro, Fluoxetine, Prozac, Sarafem, Fluvoxamine, Faverin, Fevarin, Floxyfral, Dumyrox, Luvox, Paroxetine, Paxil, Seroxat, Sertraline, Zoloft, Vilazodone, Viibryd, Doxepin, Sinequan, Silenor | University of New Mexico, Patient-Centered Outcomes Research Institute, Montana State University, National Alliance on Mental Illness Montana, CGStat LLC, Risk Benefit Statistics LLC, National Alliance on Mental Illness New Mexico, National Alliance on Mental Illness Westside Los Angeles | Bipolar Disorder | 06/19 | 06/19 | | |
